Extended Data Fig. 3: Phenotypic changes in T cell markers from pre- to post-treatment.
From: Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
a, Gene expression levels of PDCD1 (PD-1), TNFRSF4 (b); LAG3 (c); and HAVCR2 (TIM3) (d) on bulk RNA sequencing were not different from pre- to post-treatment in pathologic complete responders vs. non-responders. Two-sided P values were calculated by Wilcoxon signed-rank test. Boxes represent median (center) and first/third quartile (bottom and top, respectively) values; Tukey whiskers represent the ± 1.5 interquartile range (IQR); individual data points are shown in dots colored by CR (blue) or NR (gray).
